Published in Vaccine Weekly, November 30th, 1998
Some sera from HIV infected individuals contain potent antibodies capable of neutralizing both wild-type and T-cell-line-adapted (TCLA) HIV-1 strains. But recipients of HIV vaccines made from the HIV gp120 envelope glycoprotein do not exhibit such strong responses.
Do the vaccines have the wrong antigen' Not according to a series of studies by Walter Reed Army Institute researchers Nicholas M. Stamatos and Thomas C. VanCott and colleagues.
Stamatos et al. found that patient sera with strong neutralizing antibody activity contains potent anti-envelope antibodies capable of virus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly